Roivant Sciences Ltd. is a biopharmaceutical company founded in 2014 by Vivek Ramaswamy and initially incorporated in Bermuda, with global headquarters in Basel, Switzerland. The company pioneered the innovative "Vant" model, a hub-and-spoke structure that creates agile, focused subsidiaries—known as Vants—each dedicated to developing specific drug candidates, often acquired from larger pharmaceutical firms and deprioritized assets. This decentralized approach combines centralized resources like capital, computational tools, and expertise with subsidiary autonomy to accelerate drug development and commercialization across therapeutic areas including immunology, dermatology, autoimmune diseases, and rare conditions.

Roivant has achieved key milestones, including early financings raising $100 million in 2015, a $1.1 billion investment from SoftBank in 2017, and a $3 billion strategic deal with Sumitomo Dainippon Pharma in 2019. It went public in 2021 via a SPAC merger and marked a transformative moment with the 2023 sale of Telavant (including RVT-3101 for inflammatory bowel disease) to Roche for $7.1 billion upfront plus milestones. Notable successes include launching VTAMA (tapinarof) cream in 2022 for plaque psoriasis—generating $66.8 million in net revenue by March 2024 before Dermavant's acquisition by Organon—and advancing pipelines like Immunovant (batoclimab and IMVT-1402 for IgG-mediated autoimmune diseases) and Priovant (brepocitinib for autoimmune conditions). As a corporate insider, Roivant recently engaged in 10% director-level trading activity at Immunovant, Inc. (IMVT), reflecting its ongoing involvement in subsidiary operations.

With a strong financial position holding approximately $6.6 billion in cash as of March 2024, Roivant continues to leverage machine learning and physics-based platforms for de-risking programs. Its mission emphasizes patient-focused innovation, entrepreneurial drive, and scientific rigor, positioning it as a drug development accelerator rather than a traditional pharma firm, with diverse leadership and a pipeline poised for expansion in 2025.

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.